Conference Coverage

Remote cognitive assessments get positive mark


 

FROM AAIC 2021

Looking toward the future

Moving forward, Dr. Cullum called for more research to design new tests to exploit the telehealth format. “I think this is a really important opportunity for new test development in neuropsychology with increasing incorporation of computerized measures and integration with more cognitive neuroscience and clinical neuropsychology principles.”

He also suggested that remote testing could be combined with neuroimaging, neuromodulation, and even portable magnetoencephalography. “These opportunities for research can enhance compliance, enhance large-scale studies to allow for the inclusion of brief cognitive outcome metrics that might not have other otherwise been [possible],” said Dr. Cullum.

During the question-and-answer session, someone asked if the momentum towards telehealth will continue once the COVID-19 pandemic recedes. “We believe telehealth is here to stay, or at least I do,” said session moderator Allison Lindauer, PhD, who was asked to comment. Dr. Lindauer is an associate professor at the Layton Aging and Alzheimer’s Disease Center in Portland, Ore.

Dr. Lindauer has also conducted studies on telehealth-delivered assessments and also found encouraging results. “Work like this says, we have confidence in our work, we can believe that what we’re assessing and what we’re doing – if we did it face to face, we would get similar results,” Dr. Lindauer said in an interview.

Plenty of challenges remain, and the most important is widely available broadband internet, said Dr. Lindauer. “We need a huge push to get broadband everywhere. Granted, you’re going to have people that don’t want to use the computer, or they’re nervous about doing it online. But in my experience, most people with enough coaching can do it and are fine with it.”

Dr. Cullum and Dr. Lindauer have no relevant financial disclosures.

Pages

Recommended Reading

Chronic stress and genetics can raise the risk of Alzheimer’s disease
MDedge Neurology
FDA updates label for controversial Alzheimer’s drug aducanumab (Aduhelm)
MDedge Neurology
FDA head calls for investigation into agency’s approval of aducanumab (Aduhelm)
MDedge Neurology
Contentious Alzheimer’s drug likely to get national coverage plan, CMS says
MDedge Neurology
Zero benefit of aducanumab for Alzheimer’s disease, expert panel rules
MDedge Neurology
Common parasite now tied to impaired cognitive function
MDedge Neurology
More on GRADE: Cognitive deficits linked to CV risk factors in T2D
MDedge Neurology
Dementia caregivers benefit from telehealth support
MDedge Neurology
First guidance on appropriate use of controversial Alzheimer’s drug
MDedge Neurology
Reducing air pollution is linked to slowed brain aging and lower dementia risk
MDedge Neurology